Defining clinical failure for salvage studies

Medical Mycology

Volumn 44, Issue SUPPL. 1, 2006, Pages 315-318

  Maschmeyer, Georg ^a   Haas, Antje ^a  

^a KLINIKUM ERNST VON BERGMANN   (Germany)

Author keywords

Definition; Failure; Invasive aspergillosis; Trial design

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BETA LACTAM ANTIBIOTIC; CASPOFUNGIN; ECHINOCANDIN; GALACTOMANNAN; ITRACONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLUS; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG PENETRATION; DRUG SUBSTITUTION; DRUG TISSUE LEVEL; DRUG TREATMENT FAILURE; FUNGAL STRAIN; FUNGUS IDENTIFICATION; GRAFT VERSUS HOST REACTION; HUMAN; LUNG ASPERGILLOSIS; MONOCYTE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PATIENT CODING; SALVAGE THERAPY; SCORING SYSTEM; TREATMENT PLANNING;

ASPERGILLUS GALACTOMANNAN; FUNGI;

EID: 33749509216     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780600835690     Document Type: Article

References (18)

1. Herbrecht, R and Denning, D W and Patterson, T F and (2002) Invasive fungal infections group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med, 347, pp. 408-415.
2. Mills, W and Chopra, R and Linch, D C and (1994) Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: A single-centre experience of 133 episodes in 116 patients Br J Haematol, 86, pp. 754-760.
3. Bowden, R and Chandrasekar, P and White, M H and (2002) A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients Clin Infect Dis, 35, pp. 359-366.
4. CornelyO A, MaertensJ, BresnikM,. Liposomal amphotericin B as initial therapy for invasive filamentous fungal infections: A randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad Trial). Blood 2005; 106, Abstr #3222.
5. Ellis, M and Spence, D and de Pauw, B and (1998) An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis Clin Infect Dis, 27, pp. 1406-1412.
6. Leenders, A C A P and Daenen, S and Jansen, R L H and (1998) Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections Br J Haematol, 103, pp. 205-212.
7. Walsh, T J and Teppler, H and Donowitz, G R and (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med, 351, pp. 1391-1402.
8. Lass-Flörl, C and Griff, K and Mayr, A and (2005) Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience Br J Haematol, 131, pp. 201-207.
9. Paterson, P J and Seaton, S and Prentice, H G and (2003) Treatment failure in invasive aspergillosis: Susceptibility of deep tissue isolates following treatment with amphotericin B J Antimicrob Chemother, 52, pp. 873-876.
10. Denning, D W and Venkateswarlu, K and Oakley, K L and (1997) Itraconazole resistance in Aspergillus fumigatus Antimicrob Agents Chemother, 41, pp. 1364-1368.
11. Patterson, T F and Boucher, H W and Herbrecht, R and (2005) European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG); Pfizer Global Aspergillus Study Group. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: Impact of other therapies on outcome Clin Infect Dis, 41, pp. 1448-1452.
12. Maertens, J and Raad, I and Petrikkos, G and (2004) Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy Clin Infect Dis, 39, pp. 1563-1571.
13. Caillot, D and Couaillier, J F and Bernard, A and (2001) Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia J Clin Oncol, 19, pp. 253-259.
14. Petraitiene, R and Petraitis, V and Groll, A H and (2002) Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia Antimicrob Agents Chemother, 46, pp. 12-23.
15. Pagano, L and Ricci, P and Nosari, A and (1995) Fatal haemoptysis in pulmonary filamentous mycosis: An underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. Gimema Infection Program (Gruppo Italiano Malattie Ematologiche dell'Adulto) Br J Haematol, 89, pp. 500-505.
16. Sulahian, A and Touratier, S and Ribaud, P. (2003) False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam N Engl J Med, 349, pp. 2366-2367.
17. Viscoli, C and Machetti, M and Cappellano, P and (2004) False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam Clin Infect Dis, 38, pp. 913-916.
18. Groll, A H and Gea-Banacloche, J C and Glasmacher, A and (2003) Clinical pharmacology of antifungal compounds Infect Dis Clin North Am, 17, pp. 159-191.